Immunophenotyping characteristics and outcome of COVID‐19 patients: peripheral blood CD8+T cell as a prognostic biomarker for patients with Nirmatrelvir

BACKGROUND: Nirmatrelvir has been authorized for the treatment of both hospitalized and non-hospitalized COVID-19 patients. However, the association between T lymphocyte subsets and the outcome of hospitalized COVID-19 patients treated with oral Nirmatrelvir has not been investigated. The objective...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yuming, Dian, Yating, Gao, Qian, Deng, Guangtong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547864/
https://www.ncbi.nlm.nih.gov/pubmed/37799722
http://dx.doi.org/10.3389/fimmu.2023.1227905

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547864/
https://www.ncbi.nlm.nih.gov/pubmed/37799722
http://dx.doi.org/10.3389/fimmu.2023.1227905

Ejemplares similares